Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Galvus Review Delayed For Safety Analysis Of Primate Skin Data

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA pushes the user fee for the DPP-4 inhibitor back until the end of February.

You may also be interested in...



Galvus “Approvable” Letter Requests Additional Study In Renal Failure Patients

Analysts indicate approval of the type 2 diabetes therapy could be delayed for a year or more.

Galvus “Approvable” Letter Requests Additional Study In Renal Failure Patients

Analysts indicate approval of the type 2 diabetes therapy could be delayed for a year or more.

Merck Builds On Januvia Momentum With Two Supplementary Claims

Recently announced sNDAs have October action dates and seek indications relating to initial and add-on use with metformin or sulfonylureas.

Related Content

Topics

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel